{"acquisitions":[],"changes":[],"country":"BE","description":"Pantera Bio is a clinical-stage biotech developing first-in-class small molecules that target the tumor microenvironment to reinvigorate exhausted immune cells in solid tumors. Its compounds work through a mechanism distinct from checkpoint inhibitors, giving it an opportunity in patients who have progressed on PD-1 therapy.","domain":"panterabio.com","employees":null,"founded":2020,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":51.184042,"lng":5.115527,"location":"Mol, Belgium","multiples":[],"name":"Pantera Bio","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":100440000,"connectionsAmong":[],"currency":"EUR","date":"2024-01-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"panterabio-com-2024-01-01-series-a","source":{"fact":"round","publisher":"sifted","retrievedAt":"2026-06-12","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"panterabio-com","sources":[{"fact":"round","publisher":"sifted","retrievedAt":"2026-06-12","status":"attributed","url":null},{"fact":"existence","publisher":"panterabio.com","retrievedAt":"2026-06-12","status":"self-reported","url":"https://panterabio.com"},{"fact":"description","publisher":"panterabio.com","retrievedAt":"2026-06-12","status":"self-reported","url":"https://panterabio.com"}],"stage":"series-a","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["unknown"],"totalRaisedUsd":100440000,"traction":[],"updatedAt":"2026-06-12","valuations":[]}